TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Intravenous Nutrition Development, Research Organization (INDRO) AB
Closing information (x1000 EUR)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
27
|
21
|
16 |
| Financial expenses |
0
|
0
|
0 |
| Earnings before taxes |
38
|
0
|
0 |
| EBITDA |
-11
|
0
|
0 |
| Total assets |
455
|
408
|
439 |
| Current assets |
56
|
10
|
6 |
| Current liabilities |
19
|
11
|
7 |
| Equity capital |
437
|
397
|
432 |
| - share capital |
18
|
18
|
20 |
| Employees (average) |
1
|
1
|
1 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
96.0%
|
97.3%
|
98.4% |
| Turnover per employee |
27
|
21
|
16 |
| Profit as a percentage of turnover |
140.7%
|
0%
|
0% |
| Return on assets (ROA) |
8.4%
|
0%
|
0% |
| Current ratio |
294.7%
|
90.9%
|
85.7% |
| Return on equity (ROE) |
8.7%
|
0%
|
0% |
| Change turnover |
6
|
6
|
4 |
| Change turnover % |
27%
|
44%
|
35% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
0%
|
0%
|
0% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.